Neurocrine Biosciences
NBIXAlgoritmens signaler
- ›Starkt 3m-momentum (+26.7%)
- ›Hög volatilitet (41% årlig)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsIs Neurocrine Biosciences (NBIX) A Bargain After Strong Q2 Results And Higher Guidance? - simplywall.st
12 h sedanIs Neurocrine Biosciences (NBIX) A Bargain After Strong Q2 Results And Higher Guidance? simplywall.st
simplywall.stNeurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain? - Yahoo Finance
1 d sedanNeurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain? Yahoo Finance
Yahoo FinanceNeurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus - simplywall.st
1 d sedanNeurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus simplywall.st
simplywall.stNeurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S - GuruFocus
2 d sedanNeurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S GuruFocus
GuruFocusNeurocrine Biosciences Slides as Q2 Results and Outlook Leave Little Room for Upside - quiverquant.com
2 d sedanNeurocrine Biosciences Slides as Q2 Results and Outlook Leave Little Room for Upside quiverquant.com
quiverquant.comNeurocrine Biosciences Q2 revenue rises 39% to $959 million - quiverquant.com
3 d sedanNeurocrine Biosciences Q2 revenue rises 39% to $959 million quiverquant.com
quiverquant.comNeurocrine Biosciences Reports Second-Quarter 2026 Financial Results
3 d sedanNeurocrine Biosciences Reports Second-Quarter 2026 Financial Results PR Newswire SAN DIEGO, July 30, 2026 Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (
Neurocrine BiosciencesPR NewswireNeurocrine Biosciences Reports Second-Quarter 2026 Financial Results - PR Newswire
3 d sedanNeurocrine Biosciences Reports Second-Quarter 2026 Financial Results PR Newswire
PR NewswireNeurocrine Biosciences Announces Key Leadership Hiring, Promotions
2026-07-23Neurocrine Biosciences Announces Key Leadership Hiring, Promotions PR Newswire SAN DIEGO, July 23, 2026 SAN DIEGO , July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today
Neurocrine BiosciencesPR NewswireNeurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
2026-07-21Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer PR Newswire SAN DIEGO, July 21, 2026 SAN DIEGO , July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) to
Neurocrine BiosciencesPR NewswireNeurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer - PR Newswire
2026-07-21Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer PR Newswire
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
2026-07-09Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, July 9, 2026 Conference Call and Webcast Scheduled for Thursday, July 30
Neurocrine BiosciencesPR NewswireNeurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
2026-07-01Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia PR Newswire SAN DIEGO, July 1, 2026 SAN DIEGO , Ju
Neurocrine BiosciencesPR NewswireSoleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
2026-06-15Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Follo
Neurocrine BiosciencesPR NewswireNeurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
2026-06-15Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 PR
Neurocrine BiosciencesPR NewswireNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
2026-06-15Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 PR Ne
Neurocrine BiosciencesPR Newswire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.